Maternal and Perinatal Medicine Research Group
Professor Wallace established the Maternal-Fetal Medicine Group (now Maternal and Perinatal Medicine) in 1996 after joining Monash University’s Department of Obstetrics and Gynaecology. The group’s original research focus on pregnancy and the fetus has expanded to include life after birth, leading to the inclusion of perinatal in its name. Improvement of maternal, fetal, and neonatal health remains the focus of the group’s work. As leaders in their field, the team continues to combine fundamental and clinical research to shape best clinical practice and improve patient care. Their impressive record for delivery of translational outcomes includes several world firsts.
Despite embracing fetal and neonatal research, the team’s central focus on the pregnant woman continues to align them with the Ritchie Centre’s Women’s Health Theme. With several other research groups evolving from the Maternal and Perinatal Medicine Research Group, they remain tightly embedded in the Centre’s broader research portfolios. These established independent groups have maintained active collaborations within the Centre.
Miller SM, Yawno T, Alers NO, Castillo-Melendez M, Supramaniam VG, Van Zyl N, Sabaretnam T, Loose JM, Drummond GR, Walker DW, Jenkin G, Wallace EM (2014) Antenatal antioxidant treatment with melatonin to decrease newborn neurodevelopmental deficits and brain injury caused by fetal growth restriction. J Pineal Research 56:282-94.
Ilancheran S, Michalska A, Peh G, Wallace EM, Pera M, Manuelpillai U (2007) Stem cells derived from human fetal membranes display multilineage differentiation potential. Biology of Reproduction 77 (3):577-588.
Edwards E, Megens A, Peek M, Wallace EM (2000) Sexual origins of placental dysfunction. Lancet 355:203-4.
Wallace EM, Baker LS (1999) Effect of antenatal betamethasone administration on placental vascular resistance. Lancet 353:1404-7.
Aitken DA, Wallace EM, Crossley JA, Swanston IA, van Parenen Y, van Maarle M, Groome NP, Macri JN, Connor JM (1996) Dimeric inhibin-A as a marker for Down’s syndrome in early pregnancy. N Engl J Med 334:1321-6.